SOHM, Inc. Announce Dr. David Zarling Onboard as Senior Product Development Advisor
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has appointed Dr. David Zarling as its Senior Product Development Advisor. Dr. Zarling brings extensive experience in biotechnology, pharmaceuticals, and nutraceuticals, having served in advisory roles at SRI International-BioSciences Division, Pangene , and Colby Pharmaceutical Company. His expertise spans product development, strategic partnering, and innovation in biologic and pharma drug solutions.
Dr. Zarling's background includes work in oncology, immunology, inflammation, infectious and neurodegenerative diseases. His appointment is expected to contribute to SOHM's product development, marketing, and sales efforts, including the company's ABBIE technology products. CEO Baron Night expressed confidence that this addition will help achieve higher revenue growth in 2024 compared to previous years.
SOHM, Inc. (OTC PINK:SHMN), una compagnia nel settore farmaceutico e biotecnologico, ha nominato il Dr. David Zarling come suo Consulente Senior per lo Sviluppo del Prodotto. Il Dr. Zarling porta con sé una vasta esperienza nel campo delle biotecnologie, dei farmaci e dei nutraceutici, avendo ricoperto ruoli di consulenza presso SRI International-BioSciences Division, Pangene e Colby Pharmaceutical Company. La sua competenza abbraccia lo sviluppo di prodotti, le alleanze strategiche e l'innovazione nelle soluzioni farmaceutiche e biologiche.
Il background del Dr. Zarling include esperienze in oncologia, immunologia, infiammazione, malattie infettive e neurodegenerative. La sua nomina è prevista per contribuire agli sforzi di sviluppo del prodotto, marketing e vendite di SOHM, inclusi i prodotti della tecnologia ABBIE dell'azienda. Il CEO Baron Night ha espresso fiducia che questa aggiunta aiuterà a raggiungere una crescita dei ricavi più elevata nel 2024 rispetto agli anni precedenti.
SOHM, Inc. (OTC PINK:SHMN), una empresa de farmacéutica y biotecnología, ha designado al Dr. David Zarling como su Asesor Senior en Desarrollo de Productos. El Dr. Zarling aporta una gran experiencia en biotecnología, medicamentos y nutracéuticos, habiendo desempeñado roles de asesoría en SRI International-BioSciences Division, Pangene y Colby Pharmaceutical Company. Su experiencia abarca el desarrollo de productos, asociaciones estratégicas e innovación en soluciones farmacéuticas y biológicas.
El historial del Dr. Zarling incluye trabajos en oncología, inmunología, inflamación, enfermedades infecciosas y neurodegenerativas. Se espera que su nombramiento contribuya al desarrollo de productos, marketing y esfuerzos de ventas de SOHM, incluidos los productos de la tecnología ABBIE de la compañía. El CEO Baron Night expresó confianza en que esta incorporación ayudará a lograr un mayor crecimiento de ingresos en 2024 en comparación con años anteriores.
SOHM, Inc. (OTC PINK:SHMN), 제약 및 생명공학 회사가 Dr. David Zarling을 수석 제품 개발 고문으로 임명했습니다. Dr. Zarling은 SRI International-BioSciences Division, Pangene 및 Colby Pharmaceutical Company에서 자문 역할을 수행한 경험을 바탕으로 생명공학, 제약 및 건강기능식품 분야에서 광범위한 경험을 가지고 있습니다. 그의 전문 분야는 제품 개발, 전략적 파트너십 및 생물학적 및 제약 약물 솔루션 분야의 혁신입니다.
Dr. Zarling의 경력에는 oncology, immunology, inflammation, infectious 및 neurodegenerative diseases에 대한 작업이 포함되어 있습니다. 그의 임명은 SOHM의 제품 개발, 마케팅 및 판매 노력, 특히 회사의 ABBIE 기술 제품에 기여할 것으로 예상됩니다. CEO Baron Night는 이번 추가가 2024년에 이전 해보다 더 높은 수익 성장을 달성하는 데 도움이 될 것이라고 확신했습니다.
SOHM, Inc. (OTC PINK:SHMN), une entreprise de pharmacie et de biotechnologie, a nommé le Dr. David Zarling comme Conseiller Senior en Développement de Produits. Le Dr. Zarling apporte une vaste expérience dans les secteurs de la biotechnologie, des pharmaceutiques et des nutraceutiques, ayant occupé des postes de conseil chez SRI International-BioSciences Division, Pangene et Colby Pharmaceutical Company. Son expertise couvre le développement de produits, les partenariats stratégiques et l’innovation dans les solutions biologiques et pharmaceutiques.
Le parcours du Dr. Zarling comprend des travaux en oncologie, immunologie, inflammation, maladies infectieuses et neurodégénératives. Sa nomination devrait contribuer aux efforts de développement de produits, de marketing et de ventes de SOHM, y compris les produits technologiques ABBIE de l'entreprise. Le PDG Baron Night a exprimé sa confiance que cette addition aidera à atteindre une croissance des revenus plus élevée en 2024 par rapport aux années précédentes.
SOHM, Inc. (OTC PINK:SHMN), ein Unternehmen im Bereich Pharmazeutika und Biotechnologie, hat Dr. David Zarling zum Senior Product Development Advisor ernannt. Dr. Zarling bringt umfangreiche Erfahrung in der Biotechnologie, in der Pharmazie und in Nutrazeutika mit, nachdem er Beratungsrollen bei SRI International-BioSciences Division, Pangene und Colby Pharmaceutical Company übernommen hat. Sein Fachwissen umfasst Produktentwicklung, strategische Partnerschaften und Innovationen bei biologischen und pharmazeutischen Arzneimittellösungen.
Der Hintergrund von Dr. Zarling umfasst Arbeiten in den Bereichen Onkologie, Immunologie, Entzündungen, Infektions- und neurodegenerative Erkrankungen. Seiner Ernennung wird erwartet, dass sie zu SOHMs Produktentwicklung, Marketing und Vertriebsanstrengungen beiträgt, einschließlich der ABBIE-Technologieprodukte des Unternehmens. CEO Baron Night äußerte sein Vertrauen, dass diese Ergänzung helfen wird, im Jahr 2024 ein höheres Umsatzwachstum als in den Vorjahren zu erreichen.
- Appointment of Dr. David Zarling as Senior Product Development Advisor, bringing extensive industry experience
- Potential for improved product development, marketing, and sales in pharmaceuticals, nutraceuticals, and biotech areas
- Expected contribution to higher revenue growth in 2024 compared to previous years
- Enhancement of company's capabilities in ABBIE technology products
- None.
CHINO HILLS, CA / ACCESSWIRE / October 22, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has appointed Dr. David Zarling as its Senior Product Development Advisor.
Mr. Baron Night, CEO announced today that the company has appointed Dr. David Zarling as its senior Product Advisor with immediate effects. His talent and expertise not only helps company develop, market and sell new products in pharmaceutical, nutraceuticals but also with its ABBIE technology products.
Dr. David Zarling MA PhD MBA, has multiple experiences as Advisory Board member, Chief Biotechnology, Nutraceutical & Pharmaceutical Advisor At SRI International-BioSciences Division, Pangene Corporation and Colby Pharmaceutical Company, David's initiatives successfully discovered, characterized, developed, partnered or sold novel products and product candidates. His professional management and business skills drive research and product development, alliances and revenue growth through innovative biologic and pharma drug product solutions.
David has a strong background in senior-level professional business, strategic partnering, and product leadership within pharmaceuticals, companion diagnostics, medical devices, healthcare, and biotechnology. He has identified emerging opportunities and strategic partnerships within biotech and pharma leading to significant revenue generation, advancement of innovative product portfolios and approved products. David's experience spans small molecule pharma drugs and synthetic biologics, antibiotics, proteins, nucleic acids, recombinant-gene. - cell-, -exosome- or -liposome-based therapeutics. David functioned in integral roles in development and commercialization of therapeutics products for oncology, immunology, inflammation, infectious and neurodegenerative diseases. David was successful at the University of Vermont, BA with Honors in Biology; Dartmouth College, Department of Biological Sciences, MA, Molecular Biology; Baylor College of Medicine, Department of Virology, PhD, Biochemical Virology and Tumor Virus Drug Development; University of Wisconsin-Medical School, McArdle Lab Cancer Research, Post Doctoral, Tumor Virus Genetics; Pepperdine University, Executive MBA. David held positions at University of Wisconsin Medical School, Department of Pathology, Immunobiology Research Center; Department Molecular Biology, Max Planck Institute for Biophysical Chemistry; University of California-Berkeley, School of Public Health; SRI International Biosciences Division; and as Adjunct Associate Professor of Laboratory Medicine, UCSF
With above addition of Dr. Zarling, other milestones have been achieved in terms of having the right talent with the company for its progress in pharmaceutical, nutraceuticals and biotech areas of the product development, marketing and Sales. Management remains committed to achieving higher revenue growth in 2024 compared to previous years. This includes the revenue from of our new ABBIE kits Mr. Night added.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
FAQ
Who has SOHM Inc. (SHMN) appointed as Senior Product Development Advisor?
What experience does Dr. David Zarling bring to SOHM Inc. (SHMN)?
How might Dr. Zarling's appointment impact SOHM Inc.'s (SHMN) revenue in 2024?
What areas of product development will Dr. Zarling focus on at SOHM Inc. (SHMN)?
